Salona Global Medical Device (TSE:EVMT) has released an update.
Stay Ahead of the Market:
- Discover outperforming stocks and invest smarter with Top Smart Score Stocks
- Filter, analyze, and streamline your search for investment opportunities using Tipranks' Stock Screener
Evome Medical Technologies has reported a significant 39% projected revenue increase for Q2 2024 over the previous quarter, with a robust gross margin of 36% for April and May. In a strategic move to reduce debt, the company is planning to divest certain subsidiaries including DaMar, with future financial reports to focus on core assets Biodex and Damar. CEO Mike Seckler will discuss Q1 financials, Q2 progress, and future strategies in an upcoming shareholder update call.
For further insights into TSE:EVMT stock, check out TipRanks’ Stock Analysis page.
